|Positive WB detected in||MCF-7 cells, human brain tissue, NIH/3T3 cells|
|Positive IHC detected in||human prostate cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||MCF-7 cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:10-1:100|
|Sample-dependent, check data in validation data gallery|
11503-1-AP targets FRS2 in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||FRS2 fusion protein Ag2052|
|Full Name||fibroblast growth factor receptor substrate 2|
|Calculated molecular weight||60 kDa|
|Observed molecular weight||68 kDa|
|GenBank accession number||BC021562|
|Gene ID (NCBI)||10818|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Fibroblast growth factor (FGF) receptor substrate 2 (FRS2) has an alternative name as SNT-1, it is an adapter protein that links activated FGR and NGF receptors to downstream signaling pathways. FGF receptor substrates (FRS2 and FRS3) are key adaptor proteins that mediate FGF-FGFR signalling in benign as well as malignant tissue. FRS2 is a 508 amino-acid protein,which is phosphorylated on tyrosine residues. The molecular weight of non-phosphorylated FRS2 is 57-68 kDa, but phosphorylated FRS2 is 80-90 kDa. Phosphorylation of FRS2 is associated with activation of a number of MAP kinases. Allele-specific regulation of FGFR2 mRNA expression with a mildly increased breast cancer risk has been reported.
Transcriptomics and transposon mutagenesis identify multiple mechanisms of resistance to the FGFR inhibitor AZD4547.
Genes Chromosomes Cancer
High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.